Suboptimal Health Management in the Framework of PPP Medicine

Suboptimal health (SH) can be defined as the reversible phase of the health-to-disease transition. Consequently, the time-frame between the SH condition onset and related clinically manifested disorder is the operational window to protect the affected person against the disease which he/she is predisposed to. Protection against the health-to-disease transition is a highly comprehensive approach based on predictive diagnostics and treatments tailored to the individualised patient profile. Cost-effectiveness inversely correlates with the suboptimal severity grade and level of care. The corresponding paradigm shift from reactive medical services to advanced predictive, preventive and personalised medicine (PPPM/3PM) in biomedical sciences and daily practice is promoted by the European Association for Predictive, Preventive and Personalised Medicine (EPMA), who is recognised as the world leader in PPPM. PPPM relies on a robust conceptual and technological innovation including multi-professional expertise (researchers, caregivers, educators, technologists, policy-makers, diagnostic and pharmaceutical industry), application of artificial intelligence in medicine, education provided to professionals and general population, active involvement of patient organisation and affected individuals into the doctor–patient collaborative process (participatory medicine), amongst others. Who are the beneficiaries of health-related innovation in the framework of PPPM? The joint position paper released by the EPMA J. in 2021 [1] on behalf of the Suboptimal Health Study Consortium and EPMA stated that below listed medical fields might strongly benefit from the scientific promotion and practical implementation of the SH-related innovation in the framework of 3PM: